00:06:51 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-03-28 Bokslutskommuniké 2024
2024-11-15 Kvartalsrapport 2024-Q3
2024-08-23 Kvartalsrapport 2024-Q2
2024-07-01 X-dag ordinarie utdelning MAGNA 0.00 SEK
2024-06-28 Årsstämma 2024
2024-05-17 Kvartalsrapport 2024-Q1
2024-04-26 Extra Bolagsstämma 2024
2024-03-29 Bokslutskommuniké 2023
2023-11-24 Kvartalsrapport 2023-Q3
2023-08-25 Kvartalsrapport 2023-Q2
2023-06-22 Årsstämma 2023
2023-06-01 Kvartalsrapport 2023-Q1
2023-05-16 X-dag ordinarie utdelning MAGNA 0.00 SEK
2023-03-31 Bokslutskommuniké 2022
2023-01-20 Extra Bolagsstämma 2022
2022-11-23 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-06-21 X-dag ordinarie utdelning MAGNA 0.00 SEK
2022-06-20 Årsstämma 2022
2022-05-25 Kvartalsrapport 2022-Q1
2022-02-25 Bokslutskommuniké 2021
2021-11-23 Kvartalsrapport 2021-Q3
2021-08-24 Kvartalsrapport 2021-Q2
2021-06-29 X-dag ordinarie utdelning MAGNA 0.00 SEK
2021-06-28 Årsstämma 2021
2021-05-25 Kvartalsrapport 2021-Q1
2021-03-09 Extra Bolagsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-11-27 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Magnasense är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom forskning och utveckling av olika läkemedelskandidater. Produktportföljen är bred och inkluderar huvudsakligen läkemedel för behandling av multipel skleros. Utöver huvudverksamheten erbjuds tillhörande kringtjänster. Verksamheten drivs i samarbete med övriga läkemedelsaktörer, där störst närvaro återfinns inom Norden.
2024-02-27 08:45:00
Lund February 27th 2024 – AegirBio AB is pleased to announce the appointment of Professor Iain L. C. Chapple, BDS, FDSRCPS (Glas), FDSRCS (Edin) Ph.D. CCST (Rest Dent), to the Scientific Advisory Board to support the company’s Oral Health strategy. Professor Chapple, a distinguished dental professional, brings a wealth of experience and expertise to our esteemed board and will be key to AegirBio’s strategy of measuring specific biomarkets in saliva together with its digital platform to improve overall health.

"We are thrilled to welcome Professor Iain Chapple to our Scientific Advisory Board for Oral Health. His unparalleled expertise, leadership, and commitment to advancing dental research aligns perfectly with our mission. Professor Chapple's inclusion will undoubtedly enhance our scientific vision and drive innovation in the pursuit of improved oral health for all," said Marco Witteveen CEO and Board member of AegirBio.

Formerly the Director of Research for the Institute of Clinical Sciences and Head of the Dental School (2016-2020) at Birmingham University, Professor Chapple has authored 13 textbooks and contributed 35 chapters to various publications, showcasing his commitment to advancing knowledge in the field of dentistry. He has been a prominent figure in various dental organizations, having served as the President of the IADR Periodontal Research Group (2006-2007), Treasurer, Secretary General and Scientific Advisory Committee Chair of the European Federation of Periodontology (2007-2013), and President of the British Society of Periodontology (2014-2015), among other significant roles.

His outstanding contributions to periodontal research have earned him prestigious awards, including The Royal College of Surgeons Tomes medal (2011), IADR Distinguished Scientist (2018), and EFP’s Eminence Award (2022). In recognition of his exceptional service to dentistry, Professor Chapple was also awarded an MBE in the 2022 Queens New Year’s Honour’s.

With over 250 published papers, Professor Chapple's research extends beyond traditional periodontics. He leads both a regional periodontal service and a national service for adults with Epidermolysis Bullosa, demonstrating his commitment to advancing oral health on multiple fronts.

Professor Chapple expressed his enthusiasm about joining the Scientific Advisory Board, stating, "I am honoured to be part of AegirBio's mission to advance oral health. I look forward to contributing to the innovative work and scientific impact that the company aims for."